Abstract:Background Central nervous system (CNS) tumors are the most common pediatric solid cancer type. Tissue biopsy is not always feasible for CNS tumors due to difficult location and high complication risk. Tissue biopsies also do not represent fully the heterogeneity of the tumor, which may lead to false negative or incomplete diagnosis. Platelets have been shown to interact with tumors by various mechanisms, including taking up nucleic acids. These interactions educate platelets causing changes in their gene expression leading to development of tumor educated platelets (TEPs). Consequently, these TEPs exhibit altered function and can promote tumor cell survival and metastasis. Previous studies have demonstrated that transcriptomic analysis of TEPs allows discrimination of false positive progression from actual progression in adult glioblastoma patients. In pediatric CNS tumors, TEPs have not been widely studied earlier. The aim of this study is to evaluate the potential of TEP transcriptomic analyses to distinguish the patients with CNS tumor from asymptomatic controls, and to predict tumor progression. Methods We studied eight pediatric CNS tumor patients (aged 0-18 years) including two high grade gliomas, five low grade gliomas, and one atypical teratoid rhabdoid tumor. Blood was drawn into EDTA tubes from pediatric tumor patients before the treatment initiation, and from pediatric controls without any history of tumors (n=8). Platelets were isolated from blood using double centrifugation and CD45+ leukocyte depletion. RNA was extracted from platelets and the RNA integrity and quantity was determined using Agilent 2100 Bioanalyzer. RNA sequencing (RNA-seq) libraries were constructed from 1ng of total RNA. Rsubread was used to assign RNA-seq reads to human reference genome EnsEMBL release 111 and NCBI nuclear rRNA gene models and to determine read counts per genes. Differential expression analysis was made using DESeq2 and pathway analysis was made using Enrichr. Results We observed differential expression of 42 genes (FDR<0.1), of which 27 were protein coding, in platelets from pediatric CNS tumor patients compared to controls. Out of the protein coding genes, 5 genes were down regulated, and 22 were upregulated. Pathway enrichment analysis demonstrated that various pathways were altered, such as pathways related to immune system and interleukin signaling (p<0.001) in TEPs collected from pediatric CNS tumor patients. Furthermore, our results suggested that gene expression signature of TEPs discriminated aggressive pediatric CNS malignancies from low grade tumors. Conclusions In this pilot study we demonstrated that pediatric CNS tumor patients have alterations in TEP transcriptome compared to pediatric controls. Our preliminary results are in line with previous studies of TEPs suggesting that the presence of tumor alters platelets ́ gene expression. Moreover, gene expression analysis of TEPs may be utilized as a diagnostic approach for pediatric CNS malignancies, but more validation and larger cohorts are needed before clinical use. Citation Format: Markus Talka, Amanda Holmström, Satu Långström, Matti Kankainen, Mia Westerholm-Ormio, Anu M. Suominen, Pirjo Isohanni, Pia Valle, Atte Karppinen, Päivi Koroknay-Pal, Anna Piippo-Karjalainen, Nuutti Vartiainen, Olli Tynninen, Soili Kytölä, Anna-Kaisa Anttonen, Virve Penteikäinen, Katja Eloranta. Tumor educated platelets in detecting pediatric central nervous system tumors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pediatric Cancer Research; 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl) nr A040.

Deconvolution of the tumor-educated platelet transcriptome reveals activated platelet and inflammatory cell transcript signatures

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring.

Abstract A040 Tumor educated platelets in detecting pediatric central nervous system tumors

Lessons to learn from tumor-educated platelets

Identification of Potential Tumor-Educated Platelets RNA Biomarkers in Non-Small-cell Lung Cancer by Integrated Bioinformatical Analysis.

Contents in tumor-educated platelets as the novel biosource for cancer diagnostics

TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction

The use of platelets as a clinical tool in oncology: opportunities and challenges

Platelet RNA Enables Accurate Detection of Ovarian Cancer: an Intercontinental, Biomarker Identification Study.

Application of Tumor-Educated Platelets As New Fluid Biopsy Markers in Various Tumors

Tumor-Educated Platelets As a Promising Biomarker for Blood-Based Detection of Renal Cell Carcinoma

Mass-Tagged Self-Assembled Nanoprobe Reveals the Transport of PD-L1 from Cancer Cells to Tumor-Educated Platelets

RNA profiling of blood platelets noninvasively differentiates colorectal cancer from healthy donors and noncancerous intestinal diseases: a retrospective cohort study

Bioinformatics Analysis of Tumor-Educated Platelet Micrornas in Patients with Hepatocellular Carcinoma

Tumor-Educated Platelet RNA and Circulating Free RNA: Emerging Liquid Biopsy Markers for Different Tumor Types

Development of an accurate breast cancer detection classifier based on platelet RNA

Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets

Consequences of platelet-educated cancer cells on the expression of inflammatory and metastatic glycoproteins

Abstract 6436: Tumor-educated platelets for therapy stratification of metastasized castration resistant prostate cancer (CRPC)

Evaluation of tumor-educated platelet long non-coding RNAs (lncRNAs) as potential diagnostic biomarkers for colorectal cancer